Loading
PT-1 is the trial that made hydroxyurea the first-line drug in high-risk ET: anagrelide gave more arterial clots, more serious bleeding and more progression to myelofibrosis.
PT-1 randomised 809 patients with high-risk essential thrombocythaemia to hydroxyurea or anagrelide, both with low-dose aspirin. After a median of 39 months the composite primary endpoint of arterial or venous thrombosis, serious haemorrhage or death from a thrombotic or haemorrhagic cause was more frequent on anagrelide (odds ratio 1.57); anagrelide gave more arterial clots, serious bleeding and transformation to myelofibrosis, and fewer venous clots (Harrison and colleagues, New England Journal of Medicine 2005). Registered as ISRCTN72251782.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
809 enrolled.
Odds ratio 1.57 (95% CI 1.04-2.37) versus hydroxyurea; 809 patients, median follow-up 39 months
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Arterial or venous thrombosis, serious haemorrhage, or death from thrombotic or haemorrhagic causesprimary | Anagrelide + low-dose aspirin | - | Odds ratio 1.57 (95% CI 1.04-2.37) versus hydroxyurea; 809 patients, median follow-up 39 months | - | 0.03 | link |
| Hydroxyurea + low-dose aspirin | - | - |
Shares Anagrelide, Essential thrombocythaemia (ET) and the tags essential-thrombocythaemia, mpn.
Shares Aspirin, Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Anagrelide, Hydroxyurea (hydroxycarbamide), Aspirin, Essential thrombocythaemia (ET).
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Hydroxyurea (hydroxycarbamide), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Cytotoxic chemotherapy and the tag mpn.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Hydroxyurea (hydroxycarbamide), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Anagrelide, Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).